Articles By Jack Cush, MD
Compounded Pain Cream Scams
I was methodically signing off on stack of refill requests, until I find one I don’t recognize. The patient is mine but the prescription (under my name) is not. It’s for a specialty compounded cream...
Read Article
Thalamic Currents Underlie Sleep Problems in Fibromyalgia
Sleep disruption is a core feature of fibromyalgia. People with fibromyalgia exhibit sleep brain wave patterns often disrupted by brain waves that correspond to wakefulness.
Read Article
Cancer Risk Is Both Increased and Decreased in RA
Rheumatoid arthritis patients are often said to have no or a low risk of cancer.
Read Article
Priorities for NIAMS Research Funding
Dr. Steven Katz describes how NIAMS sets priorities for investing congressionally-appropriated funds.
Read Article
More On ICD-10
Dr. Marty Bergman (see prior article) writes to remind rheumatologists that the October 1 deadline is for the date of service. If you see the patient on September 30th, but don't bill it until October 4th, you need to use ICD-9 codes.
Read Article
TIPS for Arthritis Travelers
Travel can be challenging for arthritis patients. Here are some useful tips to travel smoothly and pain free.
Read Article
Patients Unaware that Smoking Worsens IBD
Smoking is a well-known inciting or exacerbating factor in many inflammatory diseases, including rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis.
Read Article
Long-Term Safety of Rituximab
Rituximab has been used for years with good efficacy, but with several safety concerns. Van Vollenhoven and colleagues have published the cumulative clinical trial safety experience of RTX wherein 3595 patients 1–20 (average - 4) courses over 11 years [14,816 patient-years (PY)].
Read Article
Rheumatologists are Not Always Aligned with 2012 ACR Gout Guidelines
A cross-sectional survey of 309 Brazilan rheumatologists was performed to assess their compliance with the 2012 ACR guidelines on gout.
Read Article
Alemtuzumab Effective in Behcet's Syndrome
Behcet's disease is difficult to treat and often has an over-reliance on corticosteroid use. Alemtuzumab (previously known as Campath-1H) has been studed in patients with Behcet's.
Read Article
